Indian stocks: Visit www.stage2stocks.com →

Regencell Bioscience Holdings Limited

Stage 1 · Basing · week 3

As of Oct 22, 2026, Regencell Bioscience Holdings is in Stage 1, the basing phase, now in week 3 (since Oct 2, 2026). It closed at $9.81, 81.4% below its 52-week high and below its 200-day average, which is falling.

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. More about the company

$9.81
-7.63% today
$4.9B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is RGC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 28w
S2 22w
S4 13w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 10w → S1 3w → S4 28w → S1 4w → S4 3w → S1 5w → S2 5w → S3 10w → S2 1w → S3 3w → S4 9w → S1 1w → S2 22w → S3 7w → S2 7w → S3 4w → S2 13w → S3 4w → S2 7w → S3 3w → S4 13w → S1 3w current
Total tracked: 165 weeks across 22 stage runs.

RGC among Drug Manufacturers - Specialty & Generic51st of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…51RGCStage 1 · wk 329+64.0%
vs 52W High
-81.4%
$4.78 lo$52.88 hi
81.4% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 3
1w13w26w
Week 3, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-46.1%
200 DMA: $18.19 · sloping down
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.11x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↑ ⇈
Short-term trend rising strongly, and accelerating
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+64.0%
3M
+71.5%
6M
-65.3%
YTD
-52.2%
1Y
-38.8%
Scan Membership
Breakout Watch
Latest: 2025-03-20
4 appearances in last 60 days. First seen: 2022-06-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 3 · Vol 1.11x
2026-10-21S1
Wk 3 · Vol 0.99x
2026-10-20S1
Wk 3 · Vol 1.61x
2026-10-19S1
Wk 3 · Vol 3.62x
2026-10-16S1
Wk 3 · Vol 3.10x
2026-10-15S1
Wk 2 · Vol 10.16x
2026-10-14S1
Wk 2 · Vol 3.66x
2026-10-13S1
Wk 2 · Vol 3.32x
2026-10-12S1
Wk 2 · Vol 0.74x
2026-10-09S1
Wk 2 · Vol 0.67x
2026-10-08S1
Wk 1 · Vol 1.28x
2026-10-07S1
Wk 1 · Vol 0.62x
Moving averages & range
50 DMA
$6.62
200 DMA
$18.19
52W High
$52.88
52W Low
$4.78
5D Low
$9.59
Resistance levels (recent highs)
20d High
$10.62
60d High
$10.62
120d High
$31.47
250d High
$52.88
Next resistance
+8.3%
to 20d High
ROE
-128.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 363.3

Regencell Bioscience Holdings: quick answers

What stage is Regencell Bioscience Holdings in?

As of Oct 22, 2026, Regencell Bioscience Holdings (RGC) is in Stage 1, the basing phase. It entered Stage 1 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Regencell Bioscience Holdings in an uptrend?

Not yet. Regencell Bioscience Holdings is in Stage 1, a base that can come before an uptrend. It trades 46.1% below its 200-day average, which is falling.

How far is Regencell Bioscience Holdings from its 52-week high?

Regencell Bioscience Holdings closed at $9.81 on Oct 22, 2026, 81.4% below its 52-week high of $52.88. Its 52-week low is $4.78.

How has Regencell Bioscience Holdings performed over the past year?

As of Oct 22, 2026, Regencell Bioscience Holdings is down 38.8% over the past year and down 52.2% so far in 2026.

Which sector and industry is Regencell Bioscience Holdings in?

Regencell Bioscience Holdings is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.